Core Viewpoint - Neumora Therapeutics, Inc. is facing a class action lawsuit related to its IPO, alleging violations of the Securities Act of 1933 due to misleading information regarding its clinical trials and subsequent stock performance [1][3][4]. Company Overview - Neumora Therapeutics is a clinical-stage biopharmaceutical company focused on developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases [2]. - The company acquired its flagship therapeutic candidate, Navacaprant, through the acquisition of BlackThorn Therapeutics, Inc. in September 2020 [2]. IPO Details - Neumora conducted its initial public offering (IPO) on September 15, 2023, selling 14.7 million shares at a price of $17.00 per share [2]. - Following the IPO, the stock price has significantly declined, reaching a closing price of $1.91 per share on February 5, 2025, representing an 88.7% decrease from the IPO price [4]. Allegations in the Lawsuit - The lawsuit claims that the IPO offering documents were materially false and misleading, particularly regarding the Phase Two Trial inclusion criteria and the adequacy of data for predicting results in the KOASTAL-1 study [3]. - It is alleged that Neumora had to amend the original Phase Two Trial criteria to include a patient population with moderate to severe major depressive disorder to justify its Phase Three Program [3]. - The company disclosed on January 2, 2025, that the KOASTAL-1 study failed to show a statistically significant improvement on key endpoints, which contributed to the decline in stock value [4]. Legal Process - Investors who purchased Neumora common stock in connection with the IPO have until April 7, 2025, to seek appointment as lead plaintiff in the class action lawsuit [1][5]. - The lead plaintiff will represent the interests of all class members and can select a law firm of their choice for litigation [5].

Core Viewpoint - Neumora Therapeutics, Inc. is facing a federal securities class action lawsuit due to allegations of misleading statements and inadequate data regarding its clinical trials, particularly related to its experimental depression treatment, navacaprant [4][5]. Group 1: Legal Actions and Investigations - Faruqi & Faruqi, LLP is investigating potential claims against Neumora and has set an April 7, 2025 deadline for investors to seek the role of lead plaintiff in the class action [2]. - Investors who suffered losses exceeding $50,000 in Neumora's IPO are encouraged to contact the firm to discuss their legal options [1]. Group 2: Allegations Against Neumora - The complaint alleges that Neumora and its executives violated federal securities laws by making false statements and failing to disclose critical information about the Phase Two and Phase Three clinical trials [4]. - Specific allegations include the amendment of trial inclusion criteria to show statistically significant results and the lack of adequate data in the Phase Two Trials, which affected the predictability of the Phase III study results [4]. Group 3: Impact on Stock Performance - Following the announcement of the failure of navacaprant in the Phase III Koastal-1 trial, Neumora's stock price dropped by 81%, closing at $1.97 per share on January 2, 2025 [5].

NEW YORK, Feb. 20, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=130538&from=4CLASS PERIOD: T ...

RADNOR, Pa., Feb. 19, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com)  informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or aro ...

RADNOR, Pa., Feb. 17, 2025 (GLOBE NEWSWIRE) -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York against Neumora Therapeutics, Inc. (“Neumora”) (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora’s prospectus and registration statement (collectively, the “Offering Documents ...

SAN DIEGO, Feb. 15, 2025 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Neumora Therapeutics, Inc. (NASDAQ: NMRA) common stock pursuant and/or traceable to Neumora's registration statement issued in connection with Neumora's initial public offering ("IPO") held on September 15, 2023, have until April 7, 2025 to seek appointment as lead plaintiff of the Neumora class action lawsuit.  Captioned Chang v. Neumora Therapeutics, Inc., No. 25-cv-01072 (S. ...

RADNOR, Pa., Feb. 14, 2025 /PRNewswire/ -- The law firm of Kessler Topaz Meltzer & Check, LLP (www.ktmc.com) informs investors that a securities class action lawsuit has been filed against Neumora Therapeutics, Inc. ("Neumora") (NASDAQ: NMRA) on behalf of those who purchased or otherwise acquired Neumora common stock pursuant and/or traceable to Neumora's prospectus and registration statement (collectively, the "Offering Documents") issued in connection with Neumora's initial public offering held on or arou ...

NEW YORK, Feb. 14, 2025 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Neumora Therapeutics, Inc. ("Neumora Therapeutics, Inc." or the "Company") (NASDAQ: NMRA) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Neumora Therapeutics, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of a class of all persons or entities who purchased or otherwise acquired Neumora common stock pursuant and/or tra ...

Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March 3, 2025 to report its fourth quarter and full year 2024 financial results and provide a business update WATERTOWN, Mass., Feb. 13, 2025 (GLOBE NEWSWIRE) -- Neumora Therapeutics ...

NEW YORK, Feb. 13, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Neumora Therapeutics, Inc. (NASDAQ: NMRA).Shareholders who purchased shares of NMRA during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/neumora-therapeutics-inc-loss-submission-form/?id=128956&from=4CLASS PERIOD: T ...